Trial Profile
To assess efficacy of Secukinumab in patients with Juvenile Enthesitis Related Arthritis nonresponsive to Anti-TNF treatment.
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 22 Jun 2021
Price :
$35
*
At a glance
- Drugs Secukinumab (Primary)
- Indications Juvenile rheumatoid arthritis
- Focus Therapeutic Use
- 08 Jun 2021 Results published in the Clinical and Experimental Rheumatology
- 25 Nov 2018 New trial record
- 24 Oct 2018 Results (n=14) presented at the 82nd American College of Rheumatology and the 52nd Association of Rheumatology Health Professionals Annual Scientific Meeting